一品红前三季度净利亏损1.36亿元，同比减亏

Core Insights - The company reported a revenue of 814 million yuan for the first three quarters of 2025, representing a year-on-year decline of 34.35% [1] - The net profit attributable to the company was -136 million yuan, with the loss narrowing by 44.8% year-on-year [1] - As of the disclosure date, the company has obtained 16 drug registration approvals for 15 varieties, indicating a continuous enrichment of its product pipeline and categories, which enhances its core competitiveness [1]